Media reports stated Sun Pharma's manufacturing facility in Halol (Gujarat) is undergoing a surprise inspection by the US Food and Drug Administration (US FDA). The move may have been triggered by a number of recent recalls from the plant.

Commenting on the same, Sarabjit Kour Nangra, VP Research, IT, Angel Broking, said, ''Going forward, after the merger with Ranbaxy Labs, its dependence on the region would reduce to around 45% of the expected sales in FY2016. Thus the share of the plant in the overall sales would reduce going forward, while profitability could be impacted, given low profitability of Ranbaxy labs, in case of an adverse implication, though too early to call given that company has voluntary done some withdrawal and given the importance of the facility. In case of any adverse impact the company could witness a dip of around 15% from these levels. As of now we maintain a neutral view.'

Disclaimer: IRIS has taken due care and caution in compilation of data for its web site. Information has been obtained by IRIS from sources which it considers reliable. However, IRIS does not guarantee the accuracy, adequacy or completeness of any information and is not responsible for any errors or omissions or for the results obtained from the use of such information. IRIS especially states that it has no financial liability whatsoever to any user on account of the use of information provided on its website.